We are pleased to share this article out today in @CD_AACR on the preclinical development and proof-of-concept clinical activity of NVL-655 ✅4th-generation, #ALK-selective TKI ✅CNS-penetrant ✅Broad coverage of ALK fusions and mutations, including lorlatinib-refractory compound mutations 🔥Fills an important unmet need for pts with ALK+ lung cancer and other solid tumors 📢Tune in for updated prelim efficacy&safety data from the global ongoing phase I/II study (ALKOVE-1) of NVL-655 to be presented TOMORROW at #ESMO2024! @ALKPositiveinc @ALKpositiveINT @MGHCancerCenter @MassGeneralNews @alexdrilon @MSKCancerCenter @BenjaminBesseMD @MLJohnsonMD2 @DRCamidge @jii_bum_lee @ViolaWZhu aacrjournals.org/cancerdisco…

Update for RET NSCLC @CCR_AACR describes acquired resistance to selective RET inhibitors. The "RETgistry" included 109 pts with post-SRI biopsies and showed 14% with secondary RET mutations. Off target included MET (18%), KRAS (7%), CDKN2A/B (5%). aacrjournals.org/clincancerr…

Collaborative study between MGB Thoracic and Haber, Mishra, Toner and Maheswaran labs shows DLL3 CTCs are highly predictive for outcomes with tarlatamab in SCLC. Also provide insights into CRS and mechanisms of resistance. aacrjournals.org/cancerdisco…

Join us in downtown Washington, DC on Saturday October 4th for the DC Lung Cancer Conference, an @IASLC endorsed, 1-day CME meeting covering updates in lung cancer, featuring 58 thoughtful & dynamic faculty members. #DCLung25 Register today at medstarhealth.org/dclung25

Despite progress, advanced ALK+ lung cancer almost always recurs. By deeply exploring the biology of cancer cells that resist treatment, the new PoweRD 2 Cure ALK+ Lung Cancer TeamLab aims to bend the survival curve for patients - @JessicaJLinMD #RadicalCollaboration @DanaFarber, @MDAndersonNews, @kochinstitute ,@hopkinskimmel, @MSKCancerCenter, @BostonChildrens, @MGHCancerCenter, @CUCancerCenter, @VUMC_Cancer & @ALKPositiveinc

Tackling big problems requires radical collaboration 💪. The “PoweRD 2 Cure” team strives to overcome minimal residual disease (MRD) observed with #targetedtherapy in #lungcancer. Powerhouse team to conquer an urgent, unmet clinical question. @break_cancer @ALKPositiveinc

Dr. @SWaliany is one of our abstract award winners for the DF/HCC lung cancer symposium - she discussed mechanisms of resistance to first-line vs. later-line Alectinib for ALK + NSCLC @ALKPositiveinc @ALKpositiveINT @JessicaJLinMD @LeciaSequist

Stage III ALK+ NSCLC: consolidation ALK TKI v Durva v Obs @JTOonline: -67pts, ALKi=15 Durva=30 obs=22 -mrwPFS favors ALKi (NR, 95%CI 22.7-NR) v durva (11.3m HR 0.12 p=0.006) v obs (7.2m HR=0.04 p<0.0001) Small n, but useful @OncoAlert @AminNassarMD #LCSM jto.org/article/S1556-0864%2…

Nice of @JCO_ASCO to publish this acknowledgment of reviewers for 2024. The peer review process is not perfect - it takes a lot of time to properly review submitted manuscripts and this is uncompensated time. But I think there are real benefits - individually and to the field.

We are excited to share the updated efficacy&safety data of #Zidesamtinib (NVL-520), a next-generation ROS1-selective, TRK-sparing, brain-penetrant inhibitor in ROS1 fusion+ solid tumors, from the ongoing #ARROS1 global phase 1/2 trial, presented today #ESMO24 by @BenjaminBesseMD 👉 MTD not reached, RP2D selected (100 mg oral daily) 🔥 ORR 44% in pts who were heavily pretreated (1-4 prior ROS1 inhibitors), 51% if repotrectinib-naive 🔥 ORR 41% in pts who received 2 or more prior ROS1 TKIs 🔥 ORR 38% in pts post-repotrectinib and with ROS1 G2032R mutation (the most common on-target mutation resistant to earlier-generation ROS1 TKIs) ✅ CNS-active with IC-ORR of 50%, including in pts post-lorlatinib / post-repotrectinib 🌟 Safety profile very favorable, well tolerated by pts notably with sparing of TRK-mediated neuro-toxicity (‼️important in the ROS1 treatment landscape‼️) Encouraging results, warranting further investigation including in TKI-naive and TKI-pretreated settings 👏 Congratulations to @BenjaminBesseMD on the presentation 🙏 Grateful to co-investigators and patients, families and caregivers @alexdrilon B.C. Cho @DRCamidge @JoelNealMD C.C. Lin @StephenVLiu @MNagasaka S. Kao @EnriquetaFelip A.J. van der Wekken J. Bauman @ShirishGadgeel @ViolaWZhu @MGHCancerCenter @MassGeneralNews @GustaveRoussy @MSKCancerCenter @ros1cancer #LCSM

1/4 Alright, so here are my thoughts on Radiation to Residual Disease after Targeted Therapies as presented at #WCLC24. Focusing on EGFR mutant #lungcancer where we all agree, I think, that osimertinib alone cannot be the answer, right⁉️🧐 The main risk here is secondary dissemination of drug resistance clones (DF1) from originally involved anatomical sites (OF) that happens before local therapy is employed eradicate clinical oligoprogression⚠️ @SusanScottMD #LCSM

Helpful and highly clinically relevant insights presented by Dr. Todd Bauer on the kinetics and management of AEs on 1L lorlatinib in the CROWN trial. Continued updates important for patients, caregivers, clinicians. #WCLC24 @IASLC @ALKPositiveinc @ALKpositiveINT